Natixis Regeneron Pharmaceuticals, Inc. Transaction History

Natixis

$17.6 Billion
Q3 2024

A detailed history of Natixis transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Natixis holds 54,563 shares of REGN stock, worth $42.7 Million. This represents 0.33% of its overall portfolio holdings.

Number of Shares

54,563

Previous 24,244 125.06%

Holding current value

$42.7 Million

Previous $25.5 Million 125.1%

% of portfolio

0.33%

Previous 0.15%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1024.09 - $1201.76 $31 Million - $36.4 Million	30,319 Added 125.06%	54,563 $57.4 Million
Q2 2024 Aug 13, 2024	BUY	$883.2 - $1071.19 $16.6 Million - $20.1 Million	18,788 Added 344.35%	24,244 $25.5 Million
Q1 2024 May 13, 2024	SELL	$902.69 - $993.35 $15 Million - $16.5 Million	-16,576 Reduced 75.24%	5,456 $5.25 Million
Q4 2023 Feb 13, 2024	BUY	$775.18 - $881.7 $7.17 Million - $8.15 Million	9,249 Added 72.35%	22,032 $19.4 Million
Q3 2023 Nov 14, 2023	BUY	$692.45 - $844.37 $105,944 - $129,188	153 Added 1.21%	12,783 $10.5 Million
Q2 2023 Aug 11, 2023	BUY	$700.03 - $830.35 $4.87 Million - $5.78 Million	6,956 Added 122.59%	12,630 $9.08 Million
Q1 2023 May 12, 2023	SELL	$680.49 - $826.97 $15.5 Million - $18.8 Million	-22,732 Reduced 80.03%	5,674 $4.66 Million
Q4 2022 Feb 24, 2023	SELL	$705.89 - $766.39 $348,709 - $378,596	-494 Reduced 1.71%	28,406 $20.5 Million
Q4 2022 Feb 13, 2023	BUY	$705.89 - $766.39 $336,003 - $364,801	476 Added 1.67%	28,900 $20.9 Million
Q3 2022 Nov 14, 2022	SELL	$573.97 - $724.32 $12.2 Million - $15.4 Million	-21,273 Reduced 42.81%	28,424 $19.7 Million
Q2 2022 Aug 12, 2022	SELL	$548.35 - $738.84 $45.1 Million - $60.7 Million	-82,172 Reduced 62.31%	49,697 $29.4 Million
Q1 2022 May 13, 2022	BUY	$595.12 - $698.43 $67.7 Million - $79.5 Million	113,811 Added 630.25%	131,869 $92.1 Million
Q4 2021 Feb 14, 2022	BUY	$543.48 - $670.97 $2.73 Million - $3.36 Million	5,015 Added 38.45%	18,058 $11.4 Million
Q3 2021 Nov 12, 2021	BUY	$574.03 - $680.96 $7.49 Million - $8.88 Million	13,043 New	13,043 $7.89 Million
Q2 2021 Aug 13, 2021	SELL	$472.8 - $558.54 $12.6 Million - $14.9 Million	-26,725 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$446.73 - $548.2 $611,126 - $749,937	1,368 Added 5.39%	26,725 $12.6 Million
Q4 2020 Feb 12, 2021	BUY	$478.3 - $607.98 $7.22 Million - $9.18 Million	15,105 Added 147.34%	25,357 $12.3 Million
Q3 2020 Nov 12, 2020	SELL	$544.75 - $658.21 $64.1 Million - $77.5 Million	-117,743 Reduced 91.99%	10,252 $5.74 Million
Q2 2020 Aug 13, 2020	BUY	$493.32 - $643.92 $58.7 Million - $76.6 Million	119,029 Added 1327.56%	127,995 $79.8 Million
Q1 2020 May 14, 2020	BUY	$336.18 - $494.43 $1.09 Million - $1.6 Million	3,240 Added 56.58%	8,966 $4.38 Million
Q4 2019 Feb 14, 2020	SELL	$274.13 - $376.51 $14.4 Million - $19.8 Million	-52,581 Reduced 90.18%	5,726 $2.14 Million
Q2 2019 Aug 13, 2019	SELL	$299.6 - $414.82 $41,944 - $58,074	-140 Reduced 0.24%	58,307 $18.3 Million
Q1 2019 May 15, 2019	BUY	$372.08 - $439.57 $21.7 Million - $25.7 Million	58,447 New	58,447 $23.7 Million
Q4 2018 Feb 14, 2019	SELL	$335.82 - $403.04 $507,759 - $609,396	-1,512 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$351.14 - $408.51 $530,923 - $617,667	1,512 New	1,512 $611,000
Q1 2018 May 15, 2018	SELL	$315.82 - $393.78 $1.55 Million - $1.93 Million	-4,893 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$358.63 - $469.95 $5.55 Million - $7.28 Million	-15,486 Reduced 75.99%	4,893 $1.84 Million
Q3 2017 Nov 14, 2017	BUY	$431.38 - $504.0 $8.79 Million - $10.3 Million	20,379	20,379 $9.11 Million

Others Institutions Holding REGN

# of Institutions

1,524

Shares Held

84M

Call Options Held

1.14M

Put Options Held

1.48M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $83.9B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.

Account